New

ASPIRA-aXAY
with blue light protection

7.0 mm optic preloaded

ASPIRA-aXA
XL optic – vision without limits

ASPIRA-aXA

Pseudophakic reliability for you and your patients

The innovative XL optic of the ASPIRA-aXA combines the advantages of a 7.0 mm optic with the stability of the new cut-out haptic design. This posterior-chamber IOL an be conveniently implanted using small-incision technology while adhering to surgical routine.

Monofocal ASPIRA-aXA

Personal
Contact

TypeMonofocal 1-piece posterior chamber lens, foldable
Optic diameter 7.0 mm
Total diameter 11.0 mm
Material Glistening-free, hydrophilic acrylic, UV blocker
Optic features Aspherical anterior surface, aberration-free, 360° LEC barrier,
HD optic
Haptic design Cut-out haptics
Constants for IOL calculationPlease click here
XL diopter range ASPIRA-aXAPreloaded SAFELOADER®
10.0 to 30.0 D in 0.5 D steps

Compact Line
-10.0 to 9.0 D in 1.0 D steps
10.0 to 30.0 in 0.5 D steps

XL diopter range ASPIRA-aXAY YellowPreloaded SAFELOADER®
10.0 to 30.0 D in 0.5 D steps

Preloaded implantation system
SIMPLE. INTUITIVE. FAST.

SAFELOADER®

ASPIRA-aXA

MORE THAN A CONVENTIONAL IOL

The XL optic design of the posterior chamber IOL with its extended optic diameter of 7.0 mm

and permits implantation through small incisions at the same time.

ASPIRA-aXA

THE ROUTINE REMAINS

ASPIRA-aXA

PROVIDES THE SOLUTION

ASPIRA-aXA provides a custom solution for the most diverse needs. Possible applications range from standard cataract surgery to refractive surgery and combined interventions in retinal surgery.

ASPIRA-aXA

FULFILLING PATIENT REQUIREMENTS

Advantages of an XL optic

LARGE PUPILS

With its XL optic the ASPIRA-aXA provides an ideal treatment option even under poor lighting conditions.

20% of cataract patients have a scotopic pupil diameter of ≥6 mm. In 10% of patients, even the mesopic pupil is ≥6 mm.

APPROX. 20 %
SCOTOPIC PUPIL DIAMETER ≥6 mm

APPROX. 10 %
MESOPIC PUPIL DIAMETER ≥6 mm

For an untroubled visual outcome

PREVENT PHOTIC PHENOMENA

Simulated beam guidance – 6.0 mm optic

Simulated beam guidance – 7.0 mm optic

Graphic based on a simulation using Optic Studio 16.5, Zemax with a 6 mm optic (1) and a 7 mm optic (2); pupil size – both 6 mm.

ASPIRA-aXA

ELIMINATING DYSPHOTOPSIAS

The ASPIRA-aXA with its enlarged XL optic represents a promising approach to prevent negative dysphotopsia.

UP TO 20% – NEGATIVE DYSPHOTOPSIA
Almost 20% of patients notice negative dysphotopsia after implantation of a standard IOL

UP TO 3% – PERSISTENT
Nearly 3% of pseudophakic patients are severely impaired by negative dysphotopsia permanently

Negative Dysphotopsia

MULTIFACTORIAL ORIGIN

Negative dysphotopsia can occur after successful cataract sugery with IOL implantation. The reasons for development of negative dysphotopsia in pseudophakic eyes seem to be multifactorial. Discussed are among others:

A model

FOR THE DEVELOPMENT OF NEGATIVE DYSPHOTOPSIA

Numerous ray tracing analyses using standard IOLs show a non-illuminated region of the peripheral nasal retina. This “shadow” is caused by the reduced optic diameter and the central thickness of the artificial IOL compared to the natural lens.

Schematic drawing modified according to Holladay

2.5 mm pupil, 6.0 mm IOL

 

The retinal image is generated by light rays refracted by the IOL optic (areal A), as well as by light rays that hit the retinal periphery (area B) either directly or indirectly refracted by the IOL edge. The unilluminated gap between these two areas can lead to the perception of negative dysphotopsia.

ASPIRA-aXA

CLINICALLY CONVINCING

0% Negative dysphotopsia

100% Patient satisfaction

Outstanding visual results

Pseudophakic reliability

WHAT IS THE ADVANTAGE OF AN XL OPTIC?

RISK
Approx. 20% – diabetes mellitus type 2
Cases in the age group of the average cataract patient
Over 65% – develop diabetic retinopathy
In the group of diagnosed diabetics within 20 years

REASONS
For visual impairment, according to WHO, are mainly

  • diabetic retinopathy
  • myopia (with the risk of developing high myopia including resulting secondary diseases)

TENDENCY
increasing
  • Prevalence of diabetes mellitus is expected to increase by 50% by 2045
  • 10% of the world’s population is estimated to suffer from high myopia by 2050
  • PREVENTION
    An investment to the future
  • Screening and therapy reduce the risk of irreversible visual consequences
  • Timeliness and regularity are crucial
  • The panoramic IOL

    KEEPING TRANSPARENCY

    From a vitreoretinal point of view, both the surgeon and the postoperative doctor benefit from the extended fundus view. The assessment of the posterior segment of the eye and the implementation of therapeutic measures for peripheral retinal diseases can occur more conveniently.

    ASPIRA-aXA offers patients with an increased risk of ocular diseases an advantage for long-term, successful pseudophakic treatment.

    FOR AN EXCELLENT
    INTRAOPERATIVE VIEW

    Intraoperative fundus image* (1) Edge of the XL optic (2) Theoretical optic edge of a 6.0 mm IOL

     

    Intraoperative image with implanted ASPIRA-aXA** (1) Edge of the XL optic (2) Rhexis: diameter 6.0 mm

    FOR AN CONVENIENT
    POSTOPERATIVE FOLLOW-UP

    * Courtesy of Univ.-Prof. Dr. M. Bolz, Linz
    ** Courtesy of Prof. Dr. G. Duncker, Halle

    The panoramic IOL

    EXPERTS RECOMMEND

    Prof. W. Sekundo, Marburg
    “The large ASPIRA-aXA optic has proven itself in phaco-vitrectomies because it allows an edge-free view into the outer retinal periphery.”
    Personal Statement, 2018

    Univ.-Prof. Dr. Matthias Bolz, MD, Linz
    „The view into the periphery is not only important for standard funduscopy, but also for diagnostics, fluorescence angiography and above all for retinal surgery.”
    Die ASPIRA-aXA aus Sicht eines Retinologen. Presentation DOC (Internationaler Kongress der Deutschen Ophthalmochirurgen), HumanOptics Booth Lecture, Nuremberg, 2018.

    Y. Takamura, MD, PhD.
    “The creation of a larger capsulorhexis with implantation of a 7.0 mm optic IOL contributed to a larger anterior capsule opening after cataract surgery in patients with DM [diabetes mellitus].”
    Takamura, Y., et al. Large capsulorhexis with implantation of a 7,0 mm optic lens during cataract surgery in patients with diabetes mellitus. J Catract Refract Surg 2014; 40(11):1850-1856.

     

    Outstanding material meets best-in-class technology

    A MATERIAL TO WIN YOU OVER

    High transmission. High quality.

    High Abbe number. High contrast sensitivity.*

    A high Abbe number, as a quality measure of the imaging properties of IOLs, is associated with

    * Zhao, H., Mainster, M. (2007). The effect of chromatic dispersion on pseudophakic optical performance. Br J Ophthalmol. 91 (9):1225-1229.

    Easy application

    SAFE POSITIONING

    Dr. J. Schrecker, Glauchau
    „Implantation can be performed with the same incision width as with a standard IOL.”
    Personal statement, 2018

    PROVEN TO BE ROTATIONALLY STABLE

    Choose

    – AS DESIRED.

    7.0 mm optic – preloaded

    SAFELOADER®
    SIMPLE. INTUITIVE. FAST.

    The contactless preloaded implantation system offers a maximum of safety combined with its intuitive, easy handling.

    See for yourself!
    Reports from clinical application

    The space-saving model

    COMPACT LINE

    For space-saving storage even when space is at a premium – ideal for use in the inpatient sector

    Premium IOL ASPIRA-aXA

    Your advantages of the premium IOL platform

    Clinical performance

    What do the experts say?

    Dr. E. Becker/ M. Bonsemeyer, Oranienburg
    “The ASPIRA-aXA with its enlarged XL optic represents a promising approach to minimize dysphotopsia.”
    Piskula, M. Becker, E. (2018). Reduzierte pseudophake Dysphotopsien durch vergrößerte IOL-Optik. Presentation DGII 2018.

    Prof. G. Duncker, Halle
    “The patient response has been overwhelmingly positive.”
    Personal Statement, 2018

     

    Publications

    Reports from clinical application

    Borkenstein A. F., Borkenstein E. M.
    Creating Hybrid Monovision with 7.0 mm XL Optic and High-Add AMD Intraocular Lenses (XL-MAGS) in a Patient with Retinitis Pigmentosa
    Case Rep Ophthalmol 2019;10:304-311; doi: 10.1159/000503093

    Click here for full report

    ASPIRA-aXA

    Media reports

    Interview with Becker, E. & Schrecker, J.
    Improved Stability, Refractive Results With the Aspira-aXA IOL—A Novel IOL With Enlarged Optic Diameter
    Cataract Refractive Surgery Today Europe 2020; 03:23

    Click here for full article

    Interview with Bolz, M.
    aXA Good Question, Get a Good Answer
    The Ophthalmologist 2019;10:59

    Click here for full article

    This post is also available in: German

    OUR

    CUSTOMER SERVICE

    YOUR

    QUESTIONS

    Our experts support you with your questions at any time.

    *Mandatory field

    Successful Pre-Launch of the CUSTOMFLEX® ARTIFICIALIRIS in China

    News
    News

    In June 2020, HumanOptics reached a new milestone, the successful pre-launch of the CUSTOMFLEX® ARTIFICIALIRIS in China. During a web-based event, organized by our Chinese distributor Vistek Medical, 70  Chinese surgeons were trained on the application and characteristics of the CUSTOMFLEX® ARTIFICIALIRIS by the prestigious expert Stephan Kaminski, MD (Augenklinik Zürich West & Auge und […]